EN DE
Watch Voronoi Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Voronoi Co. Ltd. (310210) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Voronoi Co. Ltd. stock KRW 47,756, price KRW 105,300, that is 54.6% below the price, quality 41 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

VC Voronoi Co. Ltd. logo Thin data Nov 10, 2026

Voronoi Co. Ltd.

310210 · KQ
Very expensive, weak quality

Our calculation puts a fair price 55% below what the stock costs today.

Low debt
Revenue last quarter +30% vs. a year ago.
Quality 41/100
Fair value 47,756 KRW · Strongly overvalued
Weak Growth (revenue 3y −8.4 %/yr in KRW)
Negative free cash flow
Trails peers (2/7)
Narrow moat 9/100
Thin data
Estimate
Watch Voronoi Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

363,500 KRW 16,453 KRW Fair Value 47,756 KRW Jun 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

53‑month range 16,453 KRW – 363,500 KRW · fair‑value band 35,817 KRW – 59,695 KRW · the 105,300 KRW price screens above the 47,756 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Voronoi Co. in your weekly email

Every Wednesday you see whether Voronoi Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea.

Show moreShow less

Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis.

The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer.

Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.

Stock analysis

Voronoi Co. Ltd. (310210) currently trades at 105,300 KRW, while our estimate is 47,756 KRW, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 35,817 KRW (bear) to 59,695 KRW (bull), the price of 105,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Voronoi Co. Ltd. reported revenue of 7.5B KRW in FY2025 versus 14.8B KRW in FY2021, a compound −15.6%/yr. Reported net income was −42.7B KRW in FY2025.

Key figures

Market cap 2.2T KRW (≈ $1.7B) Small · EPS (TTM) −3,763 KRW · Return on equity −119% · Return on assets (EBIT) −36.4% (5-year average) · Operating margin −1,947% · Revenue (TTM) 4.2B KRW · Revenue growth (YoY) +29.6% · Free cash flow −73.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 71% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −55%, 310210 screens richer than that median.

Fair Value

Bear 35,817 KRW Fair Value 47,756 KRW Bull 59,695 KRW
Price 105,300 KRW · Downside -54.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 86
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 9
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 47
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 3/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+71.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−437.2% (2020) → −723.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

310210 screens overvalued: fair value 55% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Voronoi Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −54.6% · Bottom 25%
Profitability
Return on assets −24.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 29.6% · Top 25%
Balance sheet
Debt / equity 0.36× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 21.65× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)82 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 310210
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 310210
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 310210
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 310210
argenx SE ARGX $971.55 $908.40 −7% vs 310210
CSL Limited CSL A$201.68 A$181.40 −10% vs 310210
Moderna, Inc MRNA $250.83 $158.70 −37% vs 310210
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 310210
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 310210
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 310210

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Voronoi Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Voronoi Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/310210

Frequently asked questions

Is Voronoi Co. Ltd. (310210) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 47,756 KRW versus a price of 105,300 KRW, about 55% lower (overvalued).
What is the fair value of 310210?
Our estimate for Voronoi Co. Ltd. is 47,756 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 105,300 KRW.
What is the quality score of 310210?
Voronoi Co. Ltd. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Voronoi Co. Ltd. (310210)?
Our calculated price target is the estimate of 47,756 KRW (as of Nov 10, 2026). Cautious scenario 35,817 KRW, optimistic scenario 59,695 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Voronoi Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at 47,756 KRW, about 55% lower versus a price of 105,300 KRW (overvalued). Cautious scenario 35,817 KRW, optimistic scenario 59,695 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Voronoi Co. Ltd. (310210)?
Voronoi Co. Ltd. reported trailing-twelve-month revenue of about 4.2B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Voronoi Co. Ltd. (310210)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Voronoi Co. Ltd. it is 47,756 KRW per share (as of Nov 10, 2026), against a price of 105,300 KRW.
Is Voronoi Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 310210 trades above its calculated fair value: price 105,300 KRW, fair value 47,756 KRW, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 310210?
No. The price is what the market pays today (105,300 KRW); the fair value is what the company's own numbers justify (47,756 KRW). For Voronoi Co. Ltd. the two are 57,544 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Voronoi Co. Ltd. worth?
The market values Voronoi Co. Ltd. at about 2.2T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 105,300 KRW; our models calculate a fair value of 47,756 KRW per share.
What do the bullish and bearish scenarios say about 310210?
Our models span a range for Voronoi Co. Ltd.: cautious scenario 35,817 KRW, base 47,756 KRW, optimistic 59,695 KRW per share (as of Nov 10, 2026, price 105,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Voronoi Co. Ltd. (310210)?
Balance-sheet figures for Voronoi Co. Ltd. (as of Nov 10, 2026): return on equity −119.4%, debt of 0.36 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 310210 from its 52-week high?
Voronoi Co. Ltd. trades at 105,300 KRW, about 71% below its 52-week high of 363,500 KRW and 10% above the low of 95,300 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 47,756 KRW is for.
Which stocks are comparable to Voronoi Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Voronoi Co. Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 105,300 KRW, calculated fair value 47,756 KRW (−55%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Voronoi Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Voronoi Co. Ltd. (310210)?
The closing price on Nov 10, 2026 was 105,300 KRW. Our estimate is 47,756 KRW, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Voronoi Co. Ltd. right now?
The price sits above even our optimistic bull case (59,695 KRW). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Voronoi Co. Ltd.

How large is the market capitalisation of Voronoi Co. Ltd. (310210)?
The market capitalisation of Voronoi Co. Ltd. is 2.2T KRW (≈ $1.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Voronoi Co. Ltd. (310210)?
Earnings per share at Voronoi Co. Ltd. are −3,763 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Voronoi Co. Ltd. (310210)?
The return on equity (ROE) of Voronoi Co. Ltd. is −119% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Voronoi Co. Ltd. (310210)?
On an EBIT basis the return on assets of Voronoi Co. Ltd. is −36.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Voronoi Co. Ltd. (310210)?
The operating margin of Voronoi Co. Ltd. is −1,947% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Voronoi Co. Ltd. (310210)?
Revenue at Voronoi Co. Ltd. is growing +29.6% versus a year earlier (3y avg −8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Voronoi Co. Ltd. (310210) generate?
The free cash flow of Voronoi Co. Ltd. is −73.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Voronoi Co. Ltd. (310210) carry?
The net debt of Voronoi Co. Ltd. is 1.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Voronoi Co. Ltd. in the live analysis

One click puts Voronoi Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.